PYPD - PolyPid Ltd Market Cap to Sales Volume

PolyPid Ltd. is currently heavily dependent on clinical trial results amid a critical cash balance. At the same time, the brand is valued for its scientific approach to creating polymer matrices. The price-to-sales ratio shown on this GURU.Markets chart illustrates the valuation trend, where the metric confirms the current level. PolyPid Ltd. minimizes surgical risks through prolonged drug release, occupying a stable niche.

PolyPid Ltd. (PYPD): Price-to-Revenue Ratio from 07/04/2022 to 11/13/2026

Metric breakdowns and analytics for PolyPid Ltd. (PYPD)

- market price and analyst price targets:

Stock Quotes polypid.com|PYPD - Consensus Target

- market capitalization statistics:

Market Value PolyPid Limited|PYPD - Enterprise Value

- book capitalization information:

Net Assets per Share PolyPid|PYPD - Company Book Value|Market-to-Book Ratio polypid.com|PYPD - Aggregate Company Assets

- debt obligations and liquidity statistics:

- net income and valuation ratios data:

PYPD - Net Income|Expected Net Profit PolyPid Ltd.|PYPD - Price to Earnings Ratio|Price to Expected Earnings Ratio polypid.com|PYPD - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio PolyPid Limited|PYPD - Operating profit EBITDA|Earnings per share for the last 12 months PolyPid|PYPD - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months polypid.com|PYPD - Earnings per share growth in current year|Net earnings per share growth forecast for next year PolyPid Ltd.

- total revenue and sales volume data:

PYPD - Company Sales|Company Projected Revenue Volume polypid.com|PYPD - P/S Multiple|Market Cap to Projected Revenue PolyPid Limited

Fundamental company analysis:PolyPid Ltd - PYPD

The P/S multiple determines the market value of a business relative to its annual turnover. This P/S multiple chart compares current capitalization with revenue, allowing for an assessment of the premium paid per unit of sales. The trend of this ratio reflects market expectations for future earnings. For PolyPid Ltd. (PYPD), a high valuation is justified by pharmaceutical patents and strict FDA control, which create a defensive barrier against competitors.

Competitors of PolyPid Ltd.